Elicio Therapeutics Reports Mixed Phase 2 Results and Refines Phase 3 Plan for ELI-002 7P in Pancreatic Cancer
Key Highlights from the 8-K Filing and Press Release
- Phase 2 AMPLIFY-7P Study Did Not Meet Primary Endpoint: Elicio Therapeutics announced that its Phase 2 AMPLIFY-7P study of ELI-002 7P in adjuvant mutant KRAS-driven pancreatic ductal adenocarcinoma (PDAC) did not meet the pre-specified primary endpoint of disease-free survival (DFS) in the intent-to-treat (ITT) population.
- Imbalance in Prognostic Factors: The study randomization balanced most prognostic factors between treatment arms; however, the ELI-002 7P arm had a higher proportion of R1 resected patients (19% vs. 10% in the observation arm). R1 resection, indicating tumor presence at or within 1 mm of the surgical margin, is associated with a higher risk of recurrence and negatively impacted the ELI-002 arm.
- Positive Post-Hoc Analysis in R0 Resected Patients: A post-hoc analysis revealed a stronger DFS benefit in the R0 (completely resected) population, with a hazard ratio of 0.65 (p=0.048). Median DFS was 23.8 months for ELI-002 7P vs. 12.8 months for observation in this subgroup (n=121).
- Refined Phase 3 Development Strategy: Based on these findings, Elicio plans to focus its Phase 3 study on R0 resected patients (lower residual disease burden) and to extend treatment duration with additional dosing beyond the initial immunization and booster regimen. The Phase 3 trial will be a registrational study with DFS as the primary endpoint.
- Cash Runway and Strategic Initiatives: Elicio expects its current cash and equivalents to support operations into Q4 2026. The company is actively evaluating strategic financing and partnership opportunities to fund its planned Phase 3 program and broader pipeline.
- Broader Pipeline and Future Indications: Elicio intends to expand ELI-002 7P development into other KRAS-mutant cancers, such as lung and colorectal cancers, and advance other immunotherapy candidates targeting BRAF-driven cancers and p53 hotspot mutations.
- Conference Call and Webcast: Elicio hosted a conference call and webcast to discuss these results and future plans, signaling active engagement with the investment and medical communities.
Important Information for Shareholders
- Mixed Clinical Results May Affect Share Price: The failure to meet the primary endpoint in the ITT population is a negative outcome and may pressure share values. However, the positive post-hoc results in R0 resected patients provide a potential path forward and could offset some negative sentiment if the Phase 3 design is well-received by regulators and the market.
- Regulatory Engagement and Future Milestones: Elicio plans to engage with the FDA in an End-of-Phase 2 meeting to align on Phase 3 design and regulatory strategy. Successful regulatory alignment and initiation of a registrational Phase 3 trial could be significant value drivers.
- Funding and Partnership Needs: The advancement of ELI-002 7P into Phase 3 is contingent upon securing additional capital or partnerships. Any announcements in this area could have a material impact on the share price, as they directly affect the company’s ability to execute its development plan.
- Continued Pipeline Development: While ELI-002 7P remains the lead asset, the company’s intent to expand its AMP platform to other oncogenic targets signals a commitment to long-term growth and diversification.
- Forward-Looking Statements and Risks: The company highlighted the forward-looking nature of its statements regarding clinical development, regulatory engagement, and financing. Actual results may vary due to clinical, regulatory, and financial risks, as more fully discussed in the company’s filings with the SEC.
Detailed Summary of the Report
On June 15, 2026, Elicio Therapeutics filed an 8-K with the SEC and issued a press release announcing topline results from the randomized Phase 2 AMPLIFY-7P study of ELI-002 7P in adjuvant mutant KRAS-driven pancreatic ductal adenocarcinoma (PDAC). The study did not meet its primary endpoint of disease-free survival (DFS) in the intent-to-treat population, a setback for the program. However, the company noted that randomization led to an imbalance, with the ELI-002 arm containing a higher proportion of high-risk R1 resected patients, a factor known to negatively impact outcomes.
Post-hoc analyses revealed that in the R0 resected subgroup—patients with no residual tumor at the surgical margin—ELI-002 7P demonstrated a statistically significant improvement in DFS, suggesting the drug may be more effective in patients with lower residual disease burden. The median DFS in this group was nearly doubled compared to observation (23.8 months vs. 12.8 months).
In response, Elicio is refining its Phase 3 development strategy to focus on R0 resected patients and plans to extend the dosing regimen. The company will initiate a registrational Phase 3 trial with DFS as the primary endpoint, contingent upon regulatory alignment and sufficient funding. Elicio’s current cash reserves are expected to last into the fourth quarter of 2026, but further capital or strategic partnerships will be needed to fully execute their development plans.
The company also reaffirmed its intention to expand the ELI-002 program to other KRAS-mutant cancers, such as lung and colorectal, and to advance additional candidates targeting BRAF and p53 mutations. Elicio cautioned investors that all forward-looking statements are subject to risks and uncertainties, as detailed in their latest SEC filings.
Shareholders should closely monitor upcoming regulatory meetings, financing announcements, and any updates on the Phase 3 trial design, as these could have significant implications for Elicio’s valuation and future prospects.
Disclaimer
This article is for informational purposes only and does not constitute investment advice. All forward-looking statements are subject to risks and uncertainties as detailed in Elicio Therapeutics’ filings with the SEC. Investors should conduct their own due diligence and consult with a financial advisor before making investment decisions.
